louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03132051: Sonographic Evaluation of Patients With Carpal Tunnel Syndrome Following Steroid Injection
Official title: Sonographic Evaluation of Patients With Carpal Tunnel Syndrome Following Steroid Injection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Carpal Tunnel Syndrome
Keywords: carpal tunnel syndrome
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2017-04-27
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: All patients received steroid injection for carpel tunnel syndrome (CTS) and ultrasonographic evaluation before and after steroid injection
Primary purpose: TREATMENT

Brief summary: The objective of this study was to assess sonographic changes of the median nerve after steroid injection for carpal tunnel syndrome.

Detailed description: Patients with CTS were recruited. The Boston Questionnaire (BQ) was administered and ultrasonographic and electrophysiological examinations were performed before and at two, six, and 12 weeks after steroid injection. Cross sectional area (CSA) was measured at 2 levels: at the tunnel inlet and in the mid-carpal tunnel. Flattening ratio (FR) was measured only in the mid-carpal tunnel. Correlation analyses between baseline ultrasonography, BQ, and electrophysiological measures were performed.

Eligibility criteria: Inclusion Criteria:

1. clinical diagnosis of CTS
2. The diagnosis of CTS was confirmed by electrophysiological tests.

Exclusion Criteria:

1. neurologic disorders that could mimic CTS such as cervical radiculopathy, polyneuropathy, proximal median nerve entrapment, or thoracic outlet syndrome
2. history of distal radius fracture
3. pregnancy or lactation
4. regular use of systemic NSAIDs or corticosteroids
5. known allergy to corticosteroids and local anesthetics.

Primary outcomes:
measure: Cross sectional area
timeFrame: 12 weeks
Secondary outcomes:
measure: flattening ratio
timeFrame: 2, 6, 12 weeks
measure: Boston Carpal Tunnel Questionnaire (BQ)
timeFrame: 2, 6, 12 weeks
measure: Median nerve distal motor latency
timeFrame: 2, 6, 12 weeks
measure: sensory nerve conduction velocity
timeFrame: 2, 6, 12 weeks
measure: compound muscle action potential amplitude (CMAP)
timeFrame: 2, 6, 12 weeks
measure: sensory nerve action potential amplitudes.
timeFrame: 2, 6, 12 weeks
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Teipei Veterans General Hospital
Study officials:
affiliation: Taipei Veteran General hospital
name: Jia chi Wang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05396651: Effect of Low Fermentable Oligosaccharides, Disaccharides ,Monosaccharides and Polyols (FODMAP) Diet on Control of Pediatric Irritable Bowel Syndrome and Quality of Life
Official title: Effect of Low Fodmap Diet on Control of Pediatric Irritable Bowel Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Irritable Bowel Syndrome
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2022-05-31
Enrollment: 80
Sex: ALL
Minimum age (years): 5
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the impact of low FODMAP diet on Health related Quality of life in children with Irritable bowel syndrome according to ROME IV criteria in a group of patients in pediatric Hospital at Ain Shams University

Detailed description: Single blinded randomized two-arm intervention study in which 42 patients with irritable bowel syndrome were enrolled to study the effect of LOW FODMAP diet ( intervention group) on their gastrointestinal symptoms and their quality of life another group of 42 patients of IBS were enrolled as a control group who were received general diet instructions and they followed the NICE guide lines for IBS management

Eligibility criteria: Inclusion Criteria:

* children aged 5-15 years old fulfilling ROME IV criteria of IBS diagnosis

Exclusion Criteria:

Patients presenting with :

* Abdominal pain or diarrhea that wakes the child from sleep
* Delay in onset or progression of puberty.
* Faltering growth.
* Family history of inflammatory bowel disease, celiac disease.
* History of significant weight loss .
* Bleeding per rectum.
* Persistence of severe vomiting or diarrhea
* . Persistent joint pain.
* Recurrent unexplained fever.
* Unexplained pallor

Primary outcomes:
measure: improvement of irritable bowel syndrome symproms
timeFrame: 6 weeks
Secondary outcomes:
measure: improve patients quality of life
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Medicine Ain Shams University
state: Abbasia
Study officials:
affiliation: faculty of medicine ain shams university
name: Diaa a Marzouk, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04932551: Perspectives and Management of Atypical Asthma
Official title: Perspectives and Management of Atypical Asthma in Chinese Specialists and Primary Care Practitioners -- A Nationwide Questionnaire Survey.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Asthma
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2021-06-21
Enrollment: 5000
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Physician

Brief summary: To evaluate the awareness/knowledge, clinical practice of atypical asthma among respiratory specialists and primary care practitioners (PCPs) in China.A total of 1166 respiratory specialists and 799 PCPs participated in the questionnaire survey via WeChat. The questionnaire included six major items, divided into physician demographic characteristics, awareness, diagnosis, medication prescription, assessment/education, and proposal.


Eligibility criteria: Inclusion Criteria:

* Grade Hospital Respiratory Doctor，Pediatrician，And doctors in primary hospitals

Exclusion Criteria:

* none

Primary outcomes:
measure: Complete the questionnaire
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: the Second Hospital Zhejiang University School of Medicine
state: Zhejiang
Study officials:
References:
Clinical trial NCT00489151: A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy
Official title: A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hepatitis B
Keywords: HBV
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
Collaborators: name: The University of Hong Kong
First posted: 2007-06-21
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Liver diseases due to hepatitis B reactivation are serious causes of morbidity and mortality in hepatitis B infected patients treated with chemotherapy. We have previously shown that with pre-emptive use of lamivudine, one can drastically reduce liver-related morbidity and mortality in such patients. However, due to the development of hepatitis B virus resistance to lamivudine, some of these hepatitis B infected patients still develop hepatitis. This is a research study aiming to compare the use of adefovir dipivoxil to lamivudine in hepatitis B infected patients treated with chemotherapy. Both of these drugs have been approved for the treatment of the hepatitis B infection in the United States, European Union and Hong Kong.

All patients who were recruited in this study will receive study medication, either lamivudine 100 mg daily or adefovir dipivoxil 10 mg daily to cover the entire period of chemotherapy for 72 weeks. All patients will be follow-up for an additional 24 weeks thereafter. Altogether, 70 subjects will be recruited from Queen Mary Hospital, Hong Kong SAR.

This is an open-label study, which means that the patients and the study doctor will know which treatment the subjects are assigned into. If a subject decides to take part in the study and is found eligible, he/she will be randomly (like flipping of coin) assigned to one of the following dose groups:

Lamivudine (100 mg) tablet Adefovir dipivoxil (10 mg) tablet


Eligibility criteria: Inclusion Criteria:

* HBsAg+, nucleoside/nucleotide analogue naïve, malignant disease for iv chemotherapy

Exclusion Criteria:

* HCV+ HDV+

Primary outcomes:
measure: To compare the development of viral resistance to anti-viral therapy: lamivudine versus adefovir dipivoxil in immunosuppressed patients
timeFrame: 72 weeks
Secondary outcomes:
measure: To assess the safety of adefovir dipivoxil in HBV seropositive patients who are planned to undergo chemotherapy, as compared to lamivudine.
timeFrame: 72 weeks
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Queen Mary Hospital
Study officials:
affiliation: Department of Medicine, Queen Mary Hospital
name: George Lau, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03590951: Anesthetic and Obstetric Outcomes in Morbidly Obese Pregnancy and Cesarean Delivery
Official title: Anesthetic and Obstetric Outcomes in Morbidly Obese Pregnant Patients Undergoing Cesarean Delivery: Retrospective Analysis of a Single Center Experience
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Morbid Obesity
Cesarean Section Complications
Pregnancy Related
Lead sponsor: Augusta University
Sponsor class: OTHER
First posted: 2018-07-18
Enrollment: 771
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Term pregnant patients who underwent cesarean section between 2015 and 2016 at Augusta University Medical center.

Brief summary: Given that morbid obesity has been strongly associated with obstetric, neonatal and anesthetic complications, and that scarce reports have evaluated anesthetic and obstetric outcomes after cesarean delivery in morbidly obese patients; This study retrospectively analyzed anesthetic, obstetric and neonatal outcomes in morbidly obese pregnant patients who underwent cesarean delivery at Augusta University Medical Center, during a 2-year period (2015-2016).

Detailed description: This study compared non-obese, obese and morbidly obese patients with respect to maternal, perinatal and anesthetic outcomes. Obstetric aspects included emergent procedure, estimated blood loss, obstetric complications, maternal disposition, length of stay and in-hospital mortality. Neonatal aspects included Apgar scores. Anesthetic aspects included anesthetic technique, intraoperative hemodynamic instability, failed regional anesthesia and anesthetic complications.

Eligibility criteria: Inclusion Criteria:

* Pregnant patients who underwent cesarean section at Augusta University Medical Center.
* Patients older than 18 years.

Exclusion Criteria:

* Gestational age \<37 weeks.
* Patients with chronic pain conditions

Primary outcomes:
measure: Obstetric complications
timeFrame: From beginning to end of cesarean section (2 hours)
Secondary outcomes:
measure: Anesthetic complications
timeFrame: From beginning to end of cesarean section (2 hours)
measure: Neonatal complications
timeFrame: 1 and 5 minutes after delivery
measure: Other anesthetic complications
timeFrame: From beginning to end of cesarean section (2 hours)
Other outcomes:
Locations:
city: Augusta
country: United States
facility: Augusta University
state: Georgia
Study officials:
affiliation: Medical College of Georgia. Augusta University
name: Efrain Riveros Perez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02691351: Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study
Official title: Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-Hodgkin T-cell Lymphoma
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2016-02-25
Enrollment: 500
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: T-cell non-Hodgkin lymphoma

Brief summary: The better understanding of non-Hodgkin T-cell lymphoma is essential for establishing effective treatment strategy for non-Hodgkin T-cell lymphoma. Therefore, the data about conical features and treatment outcomes of each subtype should be accumulated to establish treatment strategy. However, the majority of previous data for non-Hodgkin T-cell lymphoma was from small case series of single institute. Furthermore, as novel drugs were developed for the treatment of relapsed or refractory T-cell lymphoma, the date from patients who were treated with those novel drugs are especially required because their outcomes may reflect the outcomes of currently available treatments. Thus, a multinational, multicenter prospective registry study is needed to provide information useful for establishing treatment strategies for T-cell lymphoma.


Eligibility criteria: Inclusion Criteria:

* Pathologically diagnosed Mature T-cell non-Hodgkin lymphoma based on the World Health Organization classification 2008
* Newly diagnosed patients without a previous treatment history for T-cell lymphoma or relapsed/refractory T-cell lymphoma patients
* Age ≥19 years
* Written informed consent

Exclusion Criteria:

* Hodgkin lymphoma
* non-Hodgkin B-cell lymphoma
* Immature non-Hodgkin T-cell lymphoma: Precursor T-lymphoblastic lymphoma/leukemia
* Not understanding informed consent

Primary outcomes:
measure: Overall survival
timeFrame: 5 years
Secondary outcomes:
measure: Overall response rate to primary treatment and salvage treatment
timeFrame: 5 years
measure: Progression-free survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Won seog Kim, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05676151: Study of Music Therapy in Pain Rehabilitation Programs
Official title: How Efficient is Music Therapy as a Distraction Technique in the Pain Rehabilitation Program Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Music Therapy
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2023-01-09
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to measure changes in mood, symptom burden, pain level, and stress scores in patients before and after a 20-minute music therapy intervention.


Eligibility criteria: Inclusion Criteria:

* ≥ 18 years of age
* Patients that are enrolled in the Pain Rehabilitation Center, Mayo Florida

Exclusion Criteria:

- ≤ 18 years of age.

Primary outcomes:
measure: Change in mood
timeFrame: Baseline, after music intervention approximately 20 minutes
measure: Change in pain level
timeFrame: Baseline, after music intervention approximately 20 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Christopher Sletten, PhD, LP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06135051: Ultrasonic Neuromodulation for Treatment of Cognitive Impairment
Official title: Deep Brain Therapy With Low-intensity Ultrasound for Treatment of Cognitive Impairment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Alzheimer Disease
Dementia
Cognitive Impairment
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2023-11-18
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study will evaluate a new form of non-invasive deep brain therapy for individuals with Alzheimer's disease. Low-intensity transcranial focused ultrasound stimulation will first be delivered using a range of stimulation parameters during psychophysical and physiological monitoring. A well-tolerated stimulation protocol will be selected for subsequent testing in a blinded randomized sham-controlled cross-over trial. The trial will evaluate brain target engagement using magnetic resonance imaging, PET imaging, and numerical scales of cognitive performance.


Eligibility criteria: Inclusion Criteria:

* Mild cognitive impairment or mild dementia due to Alzheimer's disase (AD) with confirmed AD biomarkers (Amyloid PET or CSF)
* Age 65-80
* MOCA \> 18

Exclusion Criteria:

* Evidence of cerebral amyloid angiopathy or stroke within 1 year
* Clinical symptoms or findings suggestive of alternative diagnosis or co-pathology
* Inability to complete MRI
* Suicidal ideation

Primary outcomes:
measure: Montreal Cognitive Assessment Test for Dementia (MoCA)
timeFrame: Up to 3 months following study initiation
measure: Hamilton Depression Rating Scale (HDRS-17)
timeFrame: Up to 3 months following study initiation
measure: Amyloid PET
timeFrame: Up to 3 months following study initiation
Secondary outcomes:
measure: Hopkins Verbal Learning Test-Revised (HVLT-R)
timeFrame: Up to 3 months following study initiation
measure: Digit Span Memory Test
timeFrame: Up to 3 months following study initiation
measure: Trail Making Test, Part A and B
timeFrame: Up to 3 months following study initiation
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: University of Utah
state: Utah
Study officials:
References:
Clinical trial NCT01074151: The Cymbalta Pregnancy Registry
Official title: The Cymbalta Pregnancy Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pregnancy
Keywords: Pregnancy
pregnant
Cymbalta
Pregnancy Outcomes
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
Collaborators: name: Syneos Health
First posted: 2010-02-24
Enrollment: 144
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant patients exposed to Cymbalta (duloxetine) at any time during pregnancy, beginning on or after the first day of the last menstrual period

Brief summary: The Cymbalta Pregnancy Registry is a U.S. based Registry designed to monitor women who are exposed to Cymbalta (duloxetine) during pregnancy. This is an observational, exposure-registration and follow-up registry.


Eligibility criteria: Inclusion Criteria:

* Sufficient evidence (e.g., date or gestational age) to confirm that Cymbalta exposure occurred during pregnancy
* Sufficient data to establish in which trimester of pregnancy the exposure to Cymbalta first occurred (i.e., first, second or third trimester)
* Sufficient information to determine whether the pregnancy is prospectively or retrospectively registered (i.e., whether the outcome of pregnancy was known at the time of first contact with the Registry)
* Date the pregnancy exposure is reported to the Registry
* Source of the report (Health Care Professional or pregnant patient)
* Full contact information for the reporter and Health Care Professional willing and able to provide accurate pregnancy-related information (name, address, phone number, etc.)

Exclusion Criteria:

* Reported cases that do not meet the minimum criteria for Registry enrollment are deemed ineligible.

Primary outcomes:
measure: To estimate the risk of major congenital anomalies among pregnancies exposed to Cymbalta
timeFrame: maximum of 22 months
Secondary outcomes:
measure: To estimate risk of recognized spontaneous abortions, stillbirths, elective terminations, minor congenital anomalies, and any serious adverse pregnancy outcomes among pregnancies exposed to Cymbalta and their live births during the first year of life
timeFrame: maximum of 22 months
measure: To examine any potential impact of Cymbalta use while breastfeeding on the infant during the first year of life
timeFrame: maximum of 22 months
measure: To compare the risk of major congenital anomalies among pregnancies exposed to Cymbalta to an appropriate comparator(s) such as the Centers for Disease Control and Prevention (CDC) Metropolitan Atlanta Congenital Defects Program (MACDP)
timeFrame: maximum of 22 months
Other outcomes:
Locations:
city: Wilmington
country: United States
facility: The Cymbalta Pregnancy Registry Call Center
state: North Carolina
Study officials:
affiliation: Syneos Health
name: INC Research, LLC
role: STUDY_DIRECTOR
References:
Clinical trial NCT01024751: A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution
Official title: A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ocular Discomfort
Lead sponsor: Bausch & Lomb Incorporated
Sponsor class: INDUSTRY
First posted: 2009-12-03
Enrollment: 312
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The objective of this study is to evaluate the clinical performance of Bausch \& Lomb investigational Multi-Purpose Solution compared to Ciba Vision Multi-Purpose Solution when used by wearers of silicone hydrogel or Group IV contact lenses.


Eligibility criteria: Inclusion Criteria:

* Participants must be of legal age (at least 18) on the date the Informed Consent Form (ICF) is signed and with the capacity to provide voluntary informed consent.
* Participants must habitually use a lens care product for lens cleaning, disinfecting, and storage.
* Participants must wear a lens in each eye and each lens must be of the same manufacture and brand.
* Participants must agree to wear study lenses on a daily wear basis.
* Participants must be able and willing to comply with all treatment and follow-up/study procedures.

Exclusion Criteria:

* Participants participating in any drug or device clinical investigation within 2 weeks prior to entry into this study and/or during the period of study participation.
* Participants with any systemic disease affecting ocular health.
* Participants using any systemic or topical medications that will, in the Investigator's opinion, affect ocular physiology or lens performance.
* Participants who have had any corneal surgery (eg, refractive surgery).
* Participants who are allergic to any component in the study care products.

Primary outcomes:
measure: Comfort-related Symptoms/Complaints
timeFrame: At dispensing visit and each follow-up visit at week 2 and week 4.
Secondary outcomes:
measure: Slit Lamp Findings
timeFrame: Over all visits for 1 month
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Bausch & Lomb
state: New York
Study officials:
References: